Intriguingly, GSK-J4, a KDM6A inhibitor, failed to boost the apoptosis toward CPT treatment, implying that KDM6A activity is dispensable in ESCC (Figure 8G). Here, KDM6A is linked to esophageal squamous cell carcinoma.